Want to see DE:SRT full AI Analyst Report?
SRT Stock Chart & Stats
€174.00
-€4.00(-2.30%)
At close: 4:00 PM EDT
€174.00
-€4.00(-2.30%)
Day’s Range― - ―
52-Week Range€154.20 - €208.00
Previous CloseN/A
Volume3.81K
Average Volume (3M)5.04K
Market Cap
€15.31B
Enterprise Value€17.90K
Total Cash (Recent Filing)€306.90M
Total Debt (Recent Filing)€4.05B
Price to Earnings (P/E)87.2
Beta1.35
Next Earnings
Oct 22, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)2.83
Shares Outstanding37,440,000
10 Day Avg. Volume4,524
30 Day Avg. Volume5,035
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.3
Revenue Forecast (FY)€3.71B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthConsumables and recurring bioprocess revenue create repeat purchasing tied to each production run. This supports revenue visibility and customer retention as biopharma manufacturers standardize processes around Sartorius platforms.
Growth And Margin RecoveryImproving sales and profitability indicate recovery from the weaker 2023–2024 period. Management’s confirmed FY2026 targets also provide a durable operating framework, supported by growth in both major business segments.
Improving Cash GenerationStronger operating and free cash flow improves Sartorius’s ability to fund capital investment, support innovation and reduce debt. The equity ratio also increased to 41.6%, indicating some balance-sheet strengthening.
Bears Say
Elevated LeverageLeverage remains high for a medical-instruments supplier and limits financial flexibility if biopharma demand weakens. Interest, refinancing and investment requirements could constrain shareholder returns while profitability remains moderate.
Weak Bottom-line ConversionLow net profitability and inconsistent conversion of earnings into cash suggest that improved EBIT has not fully translated into durable financial strength. Financing, tax or other below-operating costs may continue to weigh on resilience.
Customer Delays And Mix PressureDelayed cell- and gene-therapy orders create uncertainty around the timing of recurring revenue, with some activity shifting to late 2026 or 2027. A weaker mix and ongoing investment can also restrain margins during the recovery.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €154.20 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €15.31B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Jul 23, 2026. The company reported €1.29 earnings per share for the quarter, missing the consensus estimate of €1.317 by -€0.027.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.37%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.25.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.29 in its last earnings report, missing expectations of €1.317. Following the earnings report the stock price went down -1.895%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.06%
12-Months-Change
Fundamentals
Return on Equity
0.37%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―